Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.
Détails
ID Serval
serval:BIB_CEF45CDD9853
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study.
Périodique
BMC geriatrics
ISSN
1471-2318 (Electronic)
ISSN-L
1471-2318
Statut éditorial
Publié
Date de publication
26/11/2018
Peer-reviewed
Oui
Volume
18
Numéro
1
Pages
289
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Publication Status: epublish
Résumé
The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience in the oldest-old and described the design of the EMIF-AD 90+ Study.
The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures.
The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration.
Nederlands Trial Register NTR5867 . Registered 20 May 2016.
The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment (aMCI), or possible or probable Alzheimer's Disease (AD). The study was part of the European Medical Information Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures.
The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors, hallmarks of aging and markers of neurodegeneration.
Nederlands Trial Register NTR5867 . Registered 20 May 2016.
Mots-clé
Aged, 80 and over, Alzheimer Disease/diagnostic imaging, Alzheimer Disease/epidemiology, Alzheimer Disease/metabolism, Alzheimer Disease/psychology, Amyloid beta-Peptides/metabolism, Biomarkers/metabolism, Case-Control Studies, Cognition/physiology, Cognitive Dysfunction/diagnostic imaging, Cognitive Dysfunction/epidemiology, Cognitive Dysfunction/metabolism, Cognitive Dysfunction/psychology, Female, Healthy Aging/metabolism, Healthy Aging/psychology, Humans, Male, Neuropsychological Tests, Alzheimer’s disease, Amnestic mild cognitive impairment, Amyloid, Cognitive impairment, Dementia, Magnetoencephalography (MEG), Oldest-old, Positron emission tomography, Resilience
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/07/2023 13:32
Dernière modification de la notice
10/01/2024 7:17